tirzepatide heart failure trial Lilly says weight loss drug cuts risk by 38% in ๐งฌ New data from the
Pay in 4 interest-free payments of $7.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 1 - Aug 6
Live Spec
New data from the SUMMIT trial reveals that long term tirzepatide (Zepbound) may significantly improve kidney function in patients with obesity, chronic kidney disease (CKD), and heart failure with preserved ejection fraction ( Weight loss drug tirzepatide may lower heart failure deaths Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity Related Heart Failure: SUMMIT CMR Substudy JACC Tirzepatide for Heart Failure in Patients with Obesity NEJM Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https: t.co 8joe2mst3e Editorial: Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction https: t.co hpmbSDk76L #Cardiology Has Tirzepatide Scaled the HFpEF Obesity SUMMIT?
Store: armz-ageddon.com ยท Domain: armz-ageddon.com




























